Is Werewolf Therapeutics going out of business?

Werewolf Therapeutics, Inc. (HOWL) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Werewolf Therapeutics, Inc. (HOWL) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: ROIC: -163.53%

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $22.0M of cash and short-term investments against $60.3M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-47.4% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• ROIC: -163.53%
• Interest coverage: -6.9x
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.36y
• Debt / Equity: No financial debt (debt-free)
• Return on Assets: -251.80%
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 8.22% (YoY)

Read from filings through 2026-08-21.

Price as of 2026-09-07.